Metropolitan Life Insurance CO Cardiff Oncology, Inc. Transaction History

Metropolitan Life Insurance CO

  • $252 Million
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 15, 2022
SELL
$5.18 - $7.24 $57,316 - $80,110
-11,065 Closed
0 $0
Q3 2021

Jun 21, 2023
BUY
$5.01 - $7.58 $55,435 - $83,872
11,065 New
11,065 $73,000
Q3 2021

Mar 30, 2023
BUY
$5.01 - $7.58 $55,435 - $83,872
11,065 New
11,065 $73,000
Q3 2021

Nov 15, 2021
BUY
$5.01 - $7.58 $55,435 - $83,872
11,065 New
11,065 $74,000

Others Institutions Holding CRDF

# of Institutions
125
Shares Held
25.3M
Call Options Held
866K
Put Options Held
203K
View Full List

About Cardiff Oncology, Inc.

CRDF Quotes by TradingView
  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $171M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email